Brief Intervention for OCD Fears

• Status: Suspended
• Trial end date: 2022-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The study will test the efficacy of propranolol or placebo, administered after reactivation of a previously acquired obsessive-compulsive disorder (OCD) fear, in reducing fear and avoidance in OCD.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: New York State Psychiatric Institute
• Treatments: Propranolol

Criteria

Inclusion Criteria:

• Principal Diagnosis of Obsessive-Compulsive Disorder

Exclusion Criteria:

• History of other serious psychiatric disorder

• Current Major Depressive Disorder

• Women who are pregnant or nursing

• Current use of psychiatric medication

• Persons planning to start another treatment during the study period

• Any significant medical condition that might increase the risk or participation or use of medications that might negatively interact with propranolol